First Comprehensive ADMET Analysis of 27 Kratom Oxindole Alkaloids Reveals Drug Interaction and CNS Potential

Why it matters

Kratom contains dozens of alkaloids beyond the well-known mitragynine and 7-OH. This first systematic computational analysis of 27 oxindole alkaloids reveals that many may interact with the same drug-metabolizing enzymes as common medications — critical data for anyone taking kratom alongside prescriptions.

The big picture

While mitragynine and 7-hydroxymitragynine dominate kratom research, the plant contains over 50 alkaloids. Oxindole alkaloids — a structurally distinct class — have been largely ignored in pharmacological research. This University of Alberta study fills that gap using computational ADMET modeling, which predicts how drugs are absorbed, distributed, metabolized, excreted, and whether they are toxic.

Key findings

• All 27 oxindole alkaloids showed 98% probability of being metabolized by CYP3A4 — the enzyme responsible for processing hundreds of common medications
• High CYP3A4 and CYP2D6 inhibition signals potential drug-drug interactions, especially with antidepressants, opioids, and antipsychotics
• Most compounds show >99% predicted oral absorption — strong drug-like characteristics for potential pharmaceutical development
• Blood-brain barrier penetration predicted at 82–99% for most compounds, suggesting significant CNS activity potential
• Some oxindole alkaloids may have anti-inflammatory, vasodilatory, and immune-modulating properties independent of opioid receptors
• Findings are computational only — the authors call for experimental in vitro and in vivo validation

What they say

The authors note: "Oxindole alkaloids may contribute to variability in kratom's CNS effects and interaction liability, particularly in polypharmacy settings." The study warns that kratom's safety profile cannot be attributed to mitragynine alone.

Bottom line

Kratom's underexplored oxindole alkaloids are computationally active at many of the same liver enzymes as common prescription drugs — making drug interaction risk a much bigger concern than most users and clinicians currently appreciate.